Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Liabilities and Shareholders Equity (2016 - 2025)

Traws Pharma's Liabilities and Shareholders Equity history spans 14 years, with the latest figure at $10.6 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $10.6 million for Q4 2025, down 57.47% from a year ago — trailing twelve months through Dec 2025 was $57.7 million (down 18.39% YoY), and the annual figure for FY2025 was $10.6 million, down 57.47%.
  • Liabilities and Shareholders Equity for Q4 2025 was $10.6 million at Traws Pharma, down from $12.4 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $60.0 million in Q3 2021 to a low of $8.9 million in Q3 2024.
  • The 5-year median for Liabilities and Shareholders Equity is $28.8 million (2023), against an average of $31.8 million.
  • The sharpest move saw Liabilities and Shareholders Equity skyrocketed 177.58% in 2021, then crashed 66.95% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $55.5 million in 2021, then decreased by 29.03% to $39.4 million in 2022, then crashed by 42.39% to $22.7 million in 2023, then increased by 10.05% to $25.0 million in 2024, then tumbled by 57.47% to $10.6 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $10.6 million, $12.4 million, and $15.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.